IMO-2055: Phase Ib data

Data from 15 patients with colorectal cancer who progressed following chemotherapy for advanced or metastatic disease in an open-label, dose-escalation, U.S. Phase Ib trial showed that once-weekly subcutaneous injections of 0.16, 0.32 and 0.48 mg/kg IMO-2055 plus Erbitux cetuximab and FOLFIRI chemotherapy were generally well tolerated. High-dose IMO-2055 was identified as the recommended Phase II dose.

Last year, Idera regained rights to IMO-2055 following the termination of a 2007 deal with Merck KGaA (Xetra:MRK, Darmstadt, Germany). Merck decided it would not conduct further development of the product after an increased incidence of neutropenia and electrolyte imbalances were reported in a Phase Ib trial to treat squamous cell carcinoma of the head and neck (SCCHN) (see BioCentury, July 11, 2011 & Dec. 5, 2011). ...